facet biotech Overview

Biogen makes a bid for Facet Biotech

Biogen has made a $14.50 a share unsolicited offer for Facet Biotech valuing the company at $356 million. Biogen first expressed interest in Facet in mid-August, offering $15 […]

Published on Mon, 07 Sep 2009 09:20:51 +0000

Facet Biotech receives US$15 million milestone payment from Bristol-Myers Squibb

Facet Biotech Corporation announced on January 11 2010 that it will receive a US$15 million payment from Bristol-Myers Squibb Co for work on a potential cancer drug. […]

Published on Tue, 12 Jan 2010 11:03:02 +0000

Biogen offers $356M for Facet Biotech; FACT Surges 74%; ValueHuntr Closes Position

We have exited our position in Facet Biotech (FACT) for a net gain of 58% since our posting on the company last April. Biogen Idec Inc. said Friday […]

Published on Mon, 07 Sep 2009 04:33:22 +0000

Update on Facet Biotech Corporation: Roderick Wong Withdraws Board Nominees

Facet Biotech Corporation (FACT) and Roderick Wong, M.D., jointly announced on Monday that based on productive discussions between Facet and Dr. Wong, Dr. Wong has withdrawn his slate […]

Published on Tue, 05 May 2009 15:26:50 +0000

Facet Biotech Corporation (NASDAQ:FACT) alternate slate withdrawn; Greenbackd exits

Dr. Roderick Wong has withdrawn his slate of director nominees for election at Facet Biotech Corporation's (NASDAQ:FACT) 2009 annual meeting of stockholders. Wong's withdrawal means that our investment […]

Published on Thu, 07 May 2009 05:00:41 +0000

Special situation: Facet Biotech Corporation (NASDAQ:FACT)

Facet Biotech Corporation (NASDAQ:FACT) is a new category of investment for us: special situations. It's an activist play with a catalyst in the form of Dr. Roderick Wong's […]

Published on Wed, 22 Apr 2009 05:01:26 +0000

BioTech Hostile Takeover: Biogen Plays For Facet

Facet Biotech Corporation (FACT) confirms that it is in receipt of Biogen Idec Inc.'s (BIIB) letter dated September 4, 2009 offering $14.50 per share for all of the […]

Published on Fri, 04 Sep 2009 19:48:35 +0000

Top Day Trader Alerts (SWHC, RGR, TTWO, BAC, MRVL, BRCM, TXN, FACT, JAVA)

These are this morning's top day trader and active trader alert stocks. We have more detailed volume data and analysis on each stock story via a link over […]

Published on Fri, 04 Dec 2009 13:52:34 +0000

Trubion Collaboration with Facet Biotech

Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) and Facet Biotech Corporation (Nasdaq: FACT) recently announced an agreement for the joint development and commercialization of TRU-016, a product candidate in phase […]

Published on Thu, 10 Sep 2009 17:36:35 +0000

Drug and Medical ? Abbott paying $450 million for Facet Biotech

NEW YORK — Drug and medical products company Abbott Laboratories said Tuesday it will buy Facet Biotech Corp. for about $450 million in cash, expanding the company’s access […]

Published on Wed, 10 Mar 2010 06:25:57 +0000

Biogen Idec shares rise on market speculation over potential ...

December 15th, 2009 Biogen threatens proxy fight in Facet bidNEW YORK — Biotechnology company Biogen Idec Inc. threatened a proxy fight Tuesday to remove a majority of Facet Biotech Corp.'s directors, heating up an already volatile ...

Published on Mon, 26 Jul 2010 17:19:41 GMT

Abbott Completes Acquisition of Facet Biotech: April 21, 2010

The final step in the acquisition process was a short-form merger of Amber Acquisition Inc., a wholly-owned subsidiary of Abbott, with and into Facet Biotech Corporation. As a result of the merger, all outstanding shares of Facet common ...

Published on Wed, 21 Apr 2010 05:00:00 GMT

Abbott Laboratories to Buy Facet Biotech for $722 Million - News ...

Under the terms of the agreement, Abbott will promptly commence a tender offer to purchase all outstanding shares of Facet Biotech at $27 per share. The closing of the tender offer is conditioned on the tender of a majority of the ...

Published on Wed, 10 Mar 2010 12:00:00 GMT

Stocks in the News: Facet Biotech, InterMune, American Eagle ...

The following is a round-up of news likely to affect stock prices today: Facet Biotech (FACT) shares soared over 67% in premarket trading after it agreed to be acquired by Abbott Laboratories (ABT) for $722 million, or $27 a share.

Published on Wed, 10 Mar 2010 12:56:00 GMT

Abbott to Buy Facet Biotech for 67% Premium - DealBook Blog ...

Abbott Laboratories announced late Tuesday that it had agreed to buy Facet Biotech for a net price of $450 million in cash, in a move aimed at expanding its drug pipeline, including for treatments for multiple sclerosis.

Published on Tue, 09 Mar 2010 23:48:58 GMT

Abbott buys Facet Biotech for $450M - FierceBiotech

Abbott has succeeded where Biogen Idec once failed. The company announced late Tuesday that it's purchasing Facet Biotech for $450 million, or $27 a share. That's 67 percent premium over the... Read more...

Published on Wed, 10 Mar 2010 00:47:06 GMT

The Facet Biotech Buyout Saga (FACT, BIIB, ABT, PDLI) : BioHealth ...

Facet Biotech Corporation (NASDAQ: FACT) is a buyout saga that seemed as though it would never end in 2009. The company is now finally being acquired, but not by Biogen Idec (NASDAQ: BIIB). Abbott Laboratories (NYSE: ABT) announced last ...

Published on Wed, 10 Mar 2010 13:30:32 GMT

Facet Biotech Has $722M That Says It Pays to Stand Up to Bullies ...

Little Facet Biotech (FACT) had to put up with some awfully patronizing statements from Biogen Idec (BIIB) when the big biotech was waging a $438 mill.

Published on Thu, 11 Mar 2010 14:51:00 GMT

Abbott Completes Acquisition of Facet Biotech

ABBOTT PARK, Illinois, April 21, 2010 - Abbott (NYSE: ABT) has completed its acquisition of Facet Biotech.